重庆西山科技股份有限公司 2025年度"提质增效重回报"行动方案的 半年度评估报告 （一）持续保持较高研发投入，推进产品全面布局 重庆西山科技股份有限公司（以下简称"公司"）为贯彻落实关于开展科 创板上市公司"提质增效重回报"专项行动的倡议，践行"以投资者为本"的 发展理念，保护所有股东的权益，基于对公司未来发展前景的信心和对公司价 值的认可，于 2025 年 4 月 29 日继续制定并实施了《重庆西山科技股份有限公 司 2025 年度"提质增效重回报"行动方案》，现将行动方案进展半年度评估情 况报告如下： 一、专注核心业务，推动募投项目建设 研发投入方面，2025 年上半年，公司继续坚持以自主研发创新的发展战略， 重视研发体系建设，研发投入金额 2,474.19 万元，同比增长 7.52%，研发投入 占营业收入比例为 15.96%，2021 年至今，研发费用已累计投入 1.85 亿元。近 年来，公司以每年超过收入 10%的研发费用投入产品研发和创新，缩短了与国 外竞品的技术差距，为后续发展储备了丰富的产品和技术。 知识产权与专利方面，2025 年上半年公司持续加强对知识产权和专利的保 护，注重知识产权和专利 ...

证券代码：688576 证券简称：西山科技 公告编号：2025-036 重庆西山科技股份有限公司 关于变更公司投资者联系方式的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重庆西山科技股份有限公司（以下简称"公司"）为更好地做好投资者关系 管理工作，便于投资者与公司沟通交流，现将公司投资者联系方式的变更情况公 告如下： | 变更事项 | 变更前 | 变更后 | | --- | --- | --- | | 投资者联系电话 | 023-68211081 | 023-65764806 | | 传真号码 | 023-68211081 | 023-65764806 | 公司网址：www.xishantech.com.cn 特此公告。 重庆西山科技股份有限公司董事会 2025 年 8 月 30 日 以上变更后的信息自本公告发布之日起正式启用。 除上述变更外，公司办公地址、电子信箱及公司网址等其他信息均保持不变。 具体情况如下： 办公地址：重庆市两江新区康美街道康竹路 2 号 电子信箱：xishangufen@xishantec ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 重庆西山科技股份有限公司（以下简称"公司"）第四届监事会第七次会议于 2025 年 8 月 29 日 14:00 以现场结合通讯会议方式在公司会议室召开。应出席会 议监事 3 名，实际出席会议监事 3 名，会议由监事会主席常婧召集和主持。会议 通知于 2025 年 8 月 19 日通过书面方式和电话等方式发出。 本次会议的召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 和《重庆西山科技股份有限公司公司章程》（以下简称"《公司章程》"）的有关 规定。 证券代码：688576 证券简称：西山科技 公告编号：2025-034 二、监事会会议审议情况 重庆西山科技股份有限公司 第四届监事会第七次会议决议公告 庆西山科技股份有限公司 2025 年半年度报告》及《重庆西山科技股份有限公司 2025 年半年度报告摘要》。 （二）审议通过《关于公司<2025 年半年度募集资金存放与实际使用情况的 专项报告>的议案》 公司基于 2025 年上半年募集资金存放 ...

Group 1 - On August 27, a block trade of 800,000 shares of Aotwei was executed, with a transaction amount of 31.68 million yuan, accounting for 7.41% of the total transaction volume for the day [1] - The transaction price was 39.6 yuan, which represents a discount of 1.02% compared to the market closing price of 40.01 yuan [1]

Company Overview - Xishan Technology's closing price on August 14 was 70.46 yuan, down 4.03%, with a rolling PE ratio of 38.05 times and a total market capitalization of 3.206 billion yuan [1] - The company operates in the surgical medical device sector, focusing on the research, manufacturing, sales, and service of surgical power devices, endoscopic systems, and energy surgical equipment [1] Financial Performance - For the first quarter of 2025, Xishan Technology reported revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% year-on-year, with a gross margin of 67.64% [1] Industry Comparison - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Xishan Technology at the 75th position in the industry ranking [1] - The company’s static PE ratio is 32.49 times, and its price-to-book ratio is 1.85 times [2]

Group 1 - The company, Xishan Technology, reported that as of August 8, 2025, the number of shareholders is 5,309 [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Xishan Technology in the medical device industry, noting its current stock price and market capitalization [1][2] - As of August 12, Xishan Technology's stock closed at 74.63 yuan, with a PE ratio of 40.30, marking a new low in 209 days, and a total market value of 3.396 billion yuan [1] - The average PE ratio for the medical device industry is 57.51, with a median of 41.25, positioning Xishan Technology at the 75th rank within the industry [1][2] Group 2 - Xishan Technology's main business involves the research, manufacturing, sales, and service of surgical medical devices, including surgical power tools, endoscopic systems, and energy surgical equipment [1] - The latest financial results for Q1 2025 show that the company achieved a revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% year-on-year, with a gross margin of 67.64% [1]

Company Overview - Xishan Technology's closing price on August 8 was 72.56 yuan, up 1.94%, with a rolling PE ratio of 39.18, marking a new low in 207 days, and a total market capitalization of 3.301 billion yuan [1] - The company operates in the surgical medical device sector, focusing on the research, manufacturing, sales, and service of surgical instruments, including surgical power devices, endoscopic systems, and energy surgical equipment [1] Financial Performance - For the first quarter of 2025, Xishan Technology reported revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% year-on-year, with a gross profit margin of 67.64% [1] Industry Comparison - The average PE ratio for the medical device industry is 55.70, with a median of 39.08, placing Xishan Technology at the 77th position in the industry ranking [1] - The company’s static PE ratio is 33.46, and its price-to-book ratio is 1.91 [2]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary of company secretaries in the medical consumables sector is 817,000 yuan [2] - Salary distribution among company secretaries is as follows: below 500,000 yuan (30%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (27%), and above 2,000,000 yuan (2%) [2] - The top three highest-paid company secretaries are: Gong Xingliang from Nanwei Medical (2.2161 million yuan), Zhu Yu from Microelectrophysiology (1.6764 million yuan), and Lin Qing from Weigao Orthopedics (1.6142 million yuan) [2] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 constitute 45%, while those over 50 account for 14%, and those aged 30-40 make up 36% [1] - The educational background of company secretaries is as follows: 7% have an associate degree, 45% hold a bachelor's degree, 43% possess a master's degree, and 5% have a doctoral degree [1] Salary Changes - Among company secretaries with over two years of tenure, the largest salary decrease was observed for Bai Xue from Xishan Technology, with a year-on-year decline of 54.09% [2] - The highest salary increase was recorded for Chen Bin from Weili Medical, with a year-on-year increase of 191.72% [2]

Group 1 - The core viewpoint of the news is that Xishan Technology's stock performance and financial metrics indicate a challenging position within the medical device industry, with a notably low PE ratio compared to industry averages [1][2] - As of August 5, Xishan Technology's closing price was 72.11 yuan, with a rolling PE ratio of 38.94, marking a 204-day low and a total market capitalization of 3.281 billion yuan [1] - The average PE ratio for the medical device industry is 54.24, with a median of 37.92, placing Xishan Technology at the 78th position in the industry ranking [1][2] Group 2 - The latest quarterly report for Q1 2025 shows Xishan Technology achieved revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% [1] - The company's gross profit margin stands at 67.64%, indicating a relatively high profitability despite the decline in revenue and net profit [1] - Xishan Technology specializes in the research, manufacturing, sales, and service of surgical medical devices, with key products including surgical power tools, endoscopic systems, and energy surgical equipment [1]